InflaRx N.V.
vilobelimab
pyoderma gangrenosum (PG)
Resolved
101days ago
Advisory committee · Mar 28, 2026
What's at stake
An FDA advisory committee reviews vilobelimab for pyoderma gangrenosum (PG) around Mar 28, 2026. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 6-K
verified 14h ago
“late-breaking abstract titled “ Vilobelimab Treatment for Ulcerative Pyoderma Gangrenosum: Results from a Multicenter, Randomized, Placebo Controlled Phase 3 Trial” has been selected for an oral presentation during the Late-Breaking Researc”